ALNY - Alnylam posts Q4 revenue beat even as annual growth slows

Alnylam Pharmaceuticals (ALNY +3.0%) is trading higher after the company reported better than expected revenue for Q4 2021, while the bottom line missed expectations amid a rise in the cost base. Quarterly revenue climbed ~58% YoY to $258.5M expanding the annual revenue by ~71% YoY to $844.3M as leading revenue generator ONPATTRO generated $139M and $475M with ~15% YoY and ~55% YoY growth, respectively. The RNAi therapeutics company managed to double its revenue in both 2019 and 2020. Total product revenue in Q4 and 2021 gained ~76% YoY and ~83% YoY, to $198.5M and $662.1M, respectively. However, as total operating costs and expenses climbed ~27% YoY to $453.1M, the net loss for the quarter rose ~6% YoY to $258.5M while the yearly net loss remained flat at $852.8M. The cash, cash equivalents, and marketable securities reached $2.4B at the end of the year from $1.9B in 2020 year-end. For 2022, Alnylam (NASDAQ:ALNY)

For further details see:

Alnylam posts Q4 revenue beat even as annual growth slows